{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T23:04:50Z","timestamp":1771542290845,"version":"3.50.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["GINOP-2.3.4.-15-2016-00002"],"award-info":[{"award-number":["GINOP-2.3.4.-15-2016-00002"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["GINOP-2.3.4.-15-2016-00002"],"award-info":[{"award-number":["GINOP-2.3.4.-15-2016-00002"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["GINOP-2.3.4.-15-2016-00002"],"award-info":[{"award-number":["GINOP-2.3.4.-15-2016-00002"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ministry of Innovation of Hungary","award":["TKP2021-EGA"],"award-info":[{"award-number":["TKP2021-EGA"]}]},{"name":"Ministry of Innovation of Hungary","award":["TKP2021-EGA"],"award-info":[{"award-number":["TKP2021-EGA"]}]},{"DOI":"10.13039\/501100009232","name":"University of Debrecen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009232","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Cholecystokinin antagonists are investigated to use against pancreas and hepatocarcinomas, the risks of which are higher in obesity with poorer prognosis than in nonobese patients. We studied their effects on granulocyte\u2013macrophage progenitor (CFU-GM), the key target of myelotoxicity of chemotherapy. Colony formation of CFU-GM was studied after the same molar doses of proglumide or lorglumide (iv, 5\u00a0days). Direct toxicity of carboplatin was determined against CFU-GM progenitors of LETO rats pre-treated with proglumide or lorglumide and against progenitors of their obese counterparts OLETF rats. Cholecystokinin receptors were studied by qPCR. Proglumide and lorglumide damaged granulopoiesis\n                    <jats:italic>in vivo<\/jats:italic>\n                    and inhibited CFU-GM of LETO rats dose-dependently\n                    <jats:italic>in vitro<\/jats:italic>\n                    . The CCK-1R-selective lorglumide caused more powerful inhibition than non-selective proglumide both\n                    <jats:italic>in vitro<\/jats:italic>\n                    and\n                    <jats:italic>in vivo<\/jats:italic>\n                    . Increased carboplatin toxicity was measured\n                    <jats:italic>in vitro<\/jats:italic>\n                    against CFU-GM obtained from either proglumide or lorglumide pre-treated rats. Carboplatin toxicity was significantly higher after lorglumide than proglumide pre-treatment, which confirmed protective effects via CCK-1R. Carboplatin damage was higher on CFU-GM progenitors of OLETF rats with CCK-1R deficiency than that of LETO rats. We detected both CCK-1R and CCK-2R in progenitors of bone marrow. Gene expressions of both CCK-Rs decreased after proglumide administration. Cholecystokinin antagonists affected granulopoiesis and sensitized granulocyte\u2013macrophage progenitors against carboplatin toxicity presumably by inhibition of the protective role of cholecystokinin via CCK-1R. It is the first proof about the presence and possible role of CCK-1 receptor in granulopoiesis. These might have value if CCK antagonists are used in malignancies, obesity, or with immunosuppressive therapies.\n                  <\/jats:p>","DOI":"10.1007\/s00210-025-04391-6","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T06:02:29Z","timestamp":1751263349000},"page":"129-141","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CCK-1R-selective and non-selective cholecystokinin antagonists, lorglumide, and proglumide increased toxicity of carboplatin to granulocyte\u2013macrophage progenitor cells (CFU-GM) of bone marrow of rats"],"prefix":"10.1007","volume":"399","author":[{"given":"Be\u00e1ta","family":"Pelles-Task\u00f3","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelika","family":"Varga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krisztina","family":"G\u00e9resi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e9la","family":"Juh\u00e1sz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zolt\u00e1n","family":"Szilv\u00e1ssy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1290-5678","authenticated-orcid":false,"given":"Ilona","family":"Benk\u0151","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,30]]},"reference":[{"issue":"2","key":"4391_CR1","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1097\/00006676-199203000-00006","volume":"7","author":"JL Abbruzzese","year":"1992","unstructured":"Abbruzzese JL, Gholson CF, Daugherty K, Larson E, DuBrow R, Berlin R, Levin B (1992) A pilot clinical trial of the cholecystokinin receptor antagonist MK-329 in patients with advanced pancreatic cancer. Pancreas 7(2):165\u2013171. https:\/\/doi.org\/10.1097\/00006676-199203000-00006","journal-title":"Pancreas"},{"issue":"Suppl1","key":"4391_CR2","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1111\/j.1476-5381.2011.01649_3.x","volume":"164","author":"SPH Alexander","year":"2011","unstructured":"Alexander SPH, Mathie A, Peters JA (2011) G protein-coupled receptors. Br J Pharmacol 164(Suppl1):S5\u2013S113. https:\/\/doi.org\/10.1111\/j.1476-5381.2011.01649_3.x","journal-title":"Br J Pharmacol"},{"issue":"6","key":"4391_CR3","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1007\/s00280-019-03960-w","volume":"84","author":"LJ Appleman","year":"2019","unstructured":"Appleman LJ, Beumer JH, Jiang Y, Lin Y, Ding F, Puhalla S, Swartz L, Owonikoko TK, Donald Harvey R, Stoller R, Petro DP, Tawbi HA, Argiris A, Strychor S, Pouquet M, Kiesel B, Chen AP, Gandara D, Belani CP, Chu E, Ramalingam SS (2019) Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies. Cancer Chemother Pharmacol 84(6):1289\u20131301. https:\/\/doi.org\/10.1007\/s00280-019-03960-w","journal-title":"Cancer Chemother Pharmacol"},{"key":"4391_CR4","doi-asserted-by":"publisher","first-page":"420931","DOI":"10.5402\/2012\/420931","volume":"2012","author":"AM Azmy","year":"2012","unstructured":"Azmy AM, Nasr KE, Gobran NS, Yassin M (2012) Gemcitabine plus carboplatin in patients with advanced hepatocellular carcinoma: results of a Phase II study. ISRN Oncol 2012:420931. https:\/\/doi.org\/10.5402\/2012\/420931","journal-title":"ISRN Oncol"},{"issue":"18","key":"4391_CR5","doi-asserted-by":"publisher","first-page":"4661","DOI":"10.3390\/cancers13184661","volume":"13","author":"MJ Batty","year":"2021","unstructured":"Batty MJ, Chabrier G, Sheridan A, Gage MC (2021) Metabolic hormones modulate macrophage inflammatory responses. Cancers (Basel) 13(18):4661. https:\/\/doi.org\/10.3390\/cancers13184661","journal-title":"Cancers (Basel)"},{"issue":"5","key":"4391_CR6","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1093\/jac\/43.5.675","volume":"43","author":"I Benk\u0151","year":"1999","unstructured":"Benk\u0151 I, Hern\u00e1di F, Megyeri A, Kiss A, Somogyi G, Tegyey Z, Kraicsovits F, Kov\u00e1cs P (1999) Comparison of the toxicity of fluconazole and other azole antifungal drugs to murine and human granulocyte -macrophage progenitor cells in vitro. J Antimicrob Chemother 43(5):675\u2013681. https:\/\/doi.org\/10.1093\/jac\/43.5.675","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"4391_CR7","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.ejphar.2003.08.021","volume":"477","author":"I Benk\u0151","year":"2003","unstructured":"Benk\u0151 I, Djazayeri K, \u00c1brah\u00e1m C, Zsuga J, Szilv\u00e1ssy Z (2003) Rosiglitazone-induced protection against myelotoxicity produced by 5-fluorouracil. Eur J Pharmacol 477(2):179\u2013182. https:\/\/doi.org\/10.1016\/j.ejphar.2003.08.021","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"4391_CR8","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/sj.bjp.0705477","volume":"140","author":"V Cano","year":"2003","unstructured":"Cano V, Ezquerra L, Ramos MP, Ruiz-Gayo M (2003) Regulation of leptin distribution between plasma and cerebrospinal fluid by cholecystokinin receptors. Br J Pharmacol 140(4):647\u2013652. https:\/\/doi.org\/10.1038\/sj.bjp.0705477","journal-title":"Br J Pharmacol"},{"key":"4391_CR9","doi-asserted-by":"publisher","first-page":"175883592311637","DOI":"10.1177\/17588359231163776","volume":"15","author":"T Chaigneau","year":"2023","unstructured":"Chaigneau T, Aguilera Munoz L, Oger C, Gourdeau C, Hentic O, Laurent L, Muller N, Dioguardi Burgio M, Gagaille MP, L\u00e9vy P, Rebours V, Hammel P, de Mestier L (2023) Efficacy and tolerance of LV5FU2-carboplatin chemotherapy in patients with advanced pancreatic ductal adenocarcinoma after failure of standard regimens. Ther Adv Med Oncol 15:17588359231163776. https:\/\/doi.org\/10.1177\/17588359231163776","journal-title":"Ther Adv Med Oncol"},{"issue":"3","key":"4391_CR10","doi-asserted-by":"publisher","first-page":"692","DOI":"10.3390\/biomedicines10030692","volume":"10","author":"M-L Chang","year":"2022","unstructured":"Chang M-L (2022) Fatty pancreas-centered metabolic basis of pancreatic adenocarcinoma: from obesity, diabetes and pancreatitis to oncogenesis. Biomedicines 10(3):692. https:\/\/doi.org\/10.3390\/biomedicines10030692","journal-title":"Biomedicines"},{"issue":"8","key":"4391_CR11","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1038\/sj.bjc.6603058","volume":"94","author":"I Chau","year":"2006","unstructured":"Chau I, Cunningham D, Russell C, Norman AR, Kurzawinski T, Harper P, Harrison P, Middleton G, Daniels F, Hickish T, Prendeville J, Ross PJ, Theis B, Hull R, Walker M, Shankley N, Kalindjian B, Murray G, Gillbanks A, Black J (2006) Gastrazole (JB95008), a novel CCK2\/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials. Br J Cancer 94(8):1107\u20131115. https:\/\/doi.org\/10.1038\/sj.bjc.6603058","journal-title":"Br J Cancer"},{"key":"4391_CR12","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.3748\/wjg.v11.i17.2549","volume":"11","author":"Y-P Chen","year":"2005","unstructured":"Chen Y-P, Yang J-S, Liu D-T, Yang W-P (2005) Long-term effects of proglumide on resection of cardiac adenocarcinoma. World J Gastroenterol 11:2549\u20133255. https:\/\/doi.org\/10.3748\/wjg.v11.i17.2549","journal-title":"World J Gastroenterol"},{"key":"4391_CR13","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1073\/pnas.0712053105","volume":"105","author":"K Claycombe","year":"2008","unstructured":"Claycombe K, King LE, Fraker PJ (2008) A role for leptin in sustaining lymphopoiesis and myelopoiesis. Proc Nat Acad Sci 105:2017\u20132021. https:\/\/doi.org\/10.1073\/pnas.0712053105","journal-title":"Proc Nat Acad Sci"},{"issue":"12","key":"4391_CR14","doi-asserted-by":"publisher","first-page":"6420","DOI":"10.3390\/ijms25126420","volume":"25","author":"L De la Cruz-Color","year":"2024","unstructured":"De la Cruz-Color L, Dominguez-Rosales JA, Maldonado-Gonz\u00e1lez M, Ru\u00edz-Madrigal B, S\u00e1nchez Mu\u00f1oz MP, Zaragoza-Guerra VA, Espinoza-Padilla VH, Ruelas-Cinco EDC, Ram\u00edrez-Meza SM, Torres Baranda JR, Gonz\u00e1lez-Guti\u00e9rrez MDR, Hernandez Nazara ZH (2024) Evidence that peripheral leptin resistance in omental adipose tissue and liver correlates with MASLD in humans. Int J Mol Sci 25(12):6420. https:\/\/doi.org\/10.3390\/ijms25126420","journal-title":"Int J Mol Sci"},{"issue":"17","key":"4391_CR15","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1016\/s0024-3205(00)00799-2","volume":"67","author":"M De la Fuente","year":"2000","unstructured":"De la Fuente M, Medina S, Del Rio M, Ferr\u00e1ndez MD, Hernanz A (2000) Effect of aging on the modulation of macrophage functions by neuropeptides. Life Sci 67(17):2125\u20132135. https:\/\/doi.org\/10.1016\/s0024-3205(00)00799-2","journal-title":"Life Sci"},{"key":"4391_CR16","doi-asserted-by":"publisher","first-page":"447","DOI":"10.3945\/ajcn.117.156943","volume":"106","author":"AJ Desai","year":"2017","unstructured":"Desai AJ, Dong M, Langlai BT, Dueck AC, Miller LJ (2017) Cholecystokinin responsiveness varies across the population dependent on metabolic phenotype. Am J Clin Nutr 106:447\u2013456. https:\/\/doi.org\/10.3945\/ajcn.117.156943","journal-title":"Am J Clin Nutr"},{"issue":"1\u20133","key":"4391_CR17","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ejphar.2005.08.053","volume":"522","author":"K Djazayeri","year":"2005","unstructured":"Djazayeri K, Peitl B, N\u00e9meth J, Nagy L, Kiss A, Szab\u00f3 B, Benk\u0151 I, Szilv\u00e1ssy Z (2005) Accelerated recovery of 5-fluorouracil-damaged bone marrow after rosiglitazone treatment. Eur J Pharmacol 522(1\u20133):122\u2013129. https:\/\/doi.org\/10.1016\/j.ejphar.2005.08.053","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"4391_CR18","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1111\/cas.15310","volume":"113","author":"T Egawa-Takata","year":"2022","unstructured":"Egawa-Takata T, Ueda Y, Ito K, Hori K, Tadahiro S, Nagasawa T, Nishio S, Ushijima K, Koji N, Enomoto T, Kikuchi A, Honma S, Oishi T, Shimada M, Takei Y, Fujiwara H, Tanabe H, Okamoto A, Nishio Y, Yamada T, Kimura T (2022) Adjuvant Chemotherapy for Endometrial Cancer (ACE) trial: a randomized phase II study for advanced endometrial carcinoma. Cancer Sci 113(5):1693\u20131701. https:\/\/doi.org\/10.1111\/cas.15310","journal-title":"Cancer Sci"},{"issue":"1","key":"4391_CR19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1158\/1940-6207.CAPR-20-0220","volume":"14","author":"MD Gay","year":"2021","unstructured":"Gay MD, Safronenka A, Cao H, Liu FH, Malchiodi ZX, Tucker RD, Kroemer A, Shivapurkar N, Smith JP (2021) Targeting the cholecystokinin receptor: a novel approach for treatment and prevention of hepatocellular cancer. Cancer Prev Res (Phila) 14(1):17\u201330. https:\/\/doi.org\/10.1158\/1940-6207.CAPR-20-0220","journal-title":"Cancer Prev Res (Phila)"},{"issue":"1\u20133","key":"4391_CR20","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.ejphar.2012.09.018","volume":"696","author":"K G\u00e9resi","year":"2012","unstructured":"G\u00e9resi K, Benk\u0151 K, Szab\u00f3 B, Megyeri A, Peitl B, Szilv\u00e1ssy Z, Benk\u0151 I (2012) Toxicity of cytotoxic agents to granulocyte-macrophage progenitors is increased in obese Zucker and non-obese but insulin resistant Goto-Kakizaki rats. Eur J Pharmacol 696(1\u20133):172\u2013178. https:\/\/doi.org\/10.1016\/j.ejphar.2012.09.018","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"4391_CR21","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s00280-015-2679-x","volume":"75","author":"K G\u00e9resi","year":"2015","unstructured":"G\u00e9resi K, Megyeri A, Szab\u00f3 B, Szab\u00f3 Z, Aradi J, N\u00e9meth J, Benk\u0151 I (2015) Myelotoxicity of carboplatin is increased in vivo in db\/db mice, the animal model of obesity-associated diabetes mellitus. Cancer Chemother Pharmacol 75(3):609\u2013618. https:\/\/doi.org\/10.1007\/s00280-015-2679-x","journal-title":"Cancer Chemother Pharmacol"},{"key":"4391_CR22","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.2147\/DDDT.S155750","volume":"12","author":"C Gridelli","year":"2018","unstructured":"Gridelli C, Chen T, Ko A, O\u2019Brien ME, Ong TJ, Socinski MA, Postmus PE (2018) nab-Paclitaxel\/carboplatin in elderly patients with advanced squamous non-small cell lung cancer: a retrospective analysis of a Phase III trial. Drug des Dev Ther 12:1445\u20131451. https:\/\/doi.org\/10.2147\/DDDT.S155750","journal-title":"Drug des Dev Ther"},{"issue":"7","key":"4391_CR23","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.2337\/diabetes.52.7.1664","volume":"52","author":"S Guilmeau","year":"2003","unstructured":"Guilmeau S, Buyse M, Tsocas A, Laigneau JP, Bado A (2003) Duodenal leptin stimulates cholecystokinin secretion: evidence of a positive leptin-cholecystokinin feedback loop. Diabetes 52(7):1664\u20131672. https:\/\/doi.org\/10.2337\/diabetes.52.7.1664","journal-title":"Diabetes"},{"issue":"9","key":"4391_CR24","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1097\/COC.0000000000000388","volume":"41","author":"A Gupta","year":"2018","unstructured":"Gupta A, Das A, Majumder K, Arora N, Mayo HG, Singh PP, Beg MS, Singh S (2018) Obesity is independently associated with increased risk of hepatocellular cancer-related mortality: a systematic review and meta-analysis. Am J Clin Oncol 41(9):874\u2013881. https:\/\/doi.org\/10.1097\/COC.0000000000000388","journal-title":"Am J Clin Oncol"},{"issue":"7","key":"4391_CR25","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.1182\/blood.V88.7.2683.bloodjournal8872683","volume":"88","author":"N Iwata","year":"1996","unstructured":"Iwata N, Murayama T, Matsumori Y, Ito M, Nagata A, Taniguchi T, Chihara K, Matsuo Y, Minowada J, Matsui T (1996) Autocrine loop through cholecystokinin-B\/gastrin receptors involved in growth of human leukemia cells. Blood 88(7):2683\u20132689. https:\/\/doi.org\/10.1182\/blood.V88.7.2683.bloodjournal8872683","journal-title":"Blood"},{"issue":"11","key":"4391_CR26","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.2337\/diab.41.11.1422","volume":"41","author":"K Kawano","year":"1992","unstructured":"Kawano K, Hirashima T, Mori S, Saitoh Y, Kurosumi M, Natori T (1992) Spontaneous long-term hyperglycemic rat with diabetic complications. Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes 41(11):1422\u20131428. https:\/\/doi.org\/10.2337\/diab.41.11.1422","journal-title":"Diabetes"},{"issue":"10","key":"4391_CR27","doi-asserted-by":"publisher","first-page":"E819","DOI":"10.1152\/ajpendo.00159","volume":"309","author":"JA Lavine","year":"2015","unstructured":"Lavine JA, Kibbe CR, Baan M, Sirinvaravong S, Umhoefer HM, Engler KA, Meske LM, Sacotte KA, Erhardt DP, Davis DB (2015) Cholecystokinin expression in the \u03b2-cell leads to increased \u03b2-cell area in aged mice and protects from streptozotocin-induced diabetes and apoptosis. Am J Physiol-Endocrinol Metab 309(10):E819-828. https:\/\/doi.org\/10.1152\/ajpendo.00159","journal-title":"Am J Physiol-Endocrinol Metab"},{"issue":"6","key":"4391_CR28","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s00432-024-05825-z","volume":"150","author":"Y Liu","year":"2024","unstructured":"Liu Y, Fang SS, Zhao RS, Liu B, Jin YQ, Li Q (2024) Nab-paclitaxel plus platinum versus paclitaxel plus platinum as first-line therapy in patients with metastatic or recurrent cervical cancer. J Cancer Res Clin Oncol 150(6):321. https:\/\/doi.org\/10.1007\/s00432-024-05825-z","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"4391_CR29","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2-\u0394\u0394CT Method. Methods 25(4):402\u2013408. https:\/\/doi.org\/10.1006\/meth.2001.1262","journal-title":"Methods"},{"issue":"suppl 1","key":"4391_CR30","doi-asserted-by":"publisher","first-page":"e566s","DOI":"10.6061\/clinics\/2018\/e566s","volume":"73","author":"JA Machado-Neto","year":"2018","unstructured":"Machado-Neto JA, Fenerich BA, Rodrigues Alves APN, Fernandes JC, Scopim-Ribeiro R, Coelho-Silva JL, Traina F (2018) Insulin substrate receptor (IRS) proteins in normal and malignant hematopoiesis. Clinics (Sao Paulo) 73(suppl 1):e566s. https:\/\/doi.org\/10.6061\/clinics\/2018\/e566s","journal-title":"Clinics (Sao Paulo)"},{"key":"4391_CR31","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1530\/JOE-19-0399","volume":"244","author":"AC Martin","year":"2020","unstructured":"Martin AC, Sun EW, Keating DJ (2020) Mechanisms controlling hormone secretion in human gut and its relevance to metabolism. J Endocrinol 244:R1\u2013R15. https:\/\/doi.org\/10.1530\/JOE-19-0399","journal-title":"J Endocrinol"},{"issue":"6","key":"4391_CR32","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1007\/s10620-014-3201-8","volume":"59","author":"GL Matters","year":"2014","unstructured":"Matters GL, Cooper TK, McGovern CO, Gilius EL, Liao J, Barth BM, Kester M, Smith JP (2014) Cholecystokinin mediates progression and metastasis of pancreatic cancer associated with dietary fat. Dig Dis Sci 59(6):1180\u20131191. https:\/\/doi.org\/10.1007\/s10620-014-3201-8","journal-title":"Dig Dis Sci"},{"issue":"4","key":"4391_CR33","doi-asserted-by":"publisher","first-page":"897","DOI":"10.2337\/db11-0402","volume":"61","author":"S Miyamoto","year":"2012","unstructured":"Miyamoto S, Shikata K, Miyasaka K, Okada S, Sasaki M, Kodera R, Hirota D, Kajitani N, Takatsuka T, Kataoka HU, Nishishita S, Sato C, Funakoshi A, Nishimori H, Uchida HA, Ogawa D, Makino H (2012) Cholecystokinin plays a novel protective role in diabetic kidney through anti-inflammatory actions on macrophage: anti-inflammatory effect of cholecystokinin. Diabetes 61(4):897\u2013907. https:\/\/doi.org\/10.2337\/db11-0402","journal-title":"Diabetes"},{"key":"4391_CR34","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/0304-3940(94)90507-X","volume":"180","author":"K Miyasaka","year":"1994","unstructured":"Miyasaka K, Kanai S, Ohta M, Kawanami T, Kono A, Funakoshi A (1994) Lack of satiety effect of cholecystokinin (CCK) in a new rat model not expressing the CCK-A receptor gene. Neurosci Letters 180:143\u2013146. https:\/\/doi.org\/10.1016\/0304-3940(94)90507-X","journal-title":"Neurosci Letters"},{"issue":"2","key":"4391_CR35","doi-asserted-by":"publisher","first-page":"CD012007","DOI":"10.1002\/14651858.CD012007.pub2","volume":"2","author":"NY Ngoi","year":"2022","unstructured":"Ngoi NY, Syn NL, Goh RM, Goh BC, Huang RY, Soon YY, James E, Cook A, Clamp A, Tan DS (2022) Weekly versus tri-weekly paclitaxel with carboplatin for first-line treatment in women with epithelial ovarian cancer. Cochrane Database Syst Rev 2(2):CD012007. https:\/\/doi.org\/10.1002\/14651858.CD012007.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"1\u20133","key":"4391_CR36","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/0196-9781(84)90082-2","volume":"644","author":"B Peitl","year":"2010","unstructured":"Peitl B, D\u00f6br\u00f6nte R, Drimba L, S\u00e1ri R, Varga A, N\u00e9meth J, P\u00e1zm\u00e1ny T, Szilv\u00e1ssy Z (2010) Involvement of cholecystokinin in baseline and post-prandial whole body insulin sensitivity in rats. Eur J Pharmacol 644(1\u20133):251\u2013256. https:\/\/doi.org\/10.1016\/0196-9781(84)90082-2","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"4391_CR37","doi-asserted-by":"publisher","first-page":"e213520","DOI":"10.1001\/jamanetworkopen.2021.3520","volume":"4","author":"F Petrelli","year":"2021","unstructured":"Petrelli F, Cortellini A, Indini A, Tomasello G, Ghidini M, Nigro O, Salati M, Dottorini L, Iaculli A, Varricchio A, Rampulla V, Barni S, Cabiddu M, Bossi A, Ghidini A, Zaniboni A (2021) Association of obesity with survival outcomes in patients with cancer: a systematic review and meta-analysis. JAMA Netw Open 4(3):e213520. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.3520","journal-title":"JAMA Netw Open"},{"issue":"47","key":"4391_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fendo.2017.00047","volume":"8","author":"JF Rehfeld","year":"2017","unstructured":"Rehfeld JF (2017) Cholecystokinin-from local gut hormone to ubiquitous messenger. Front Endocrinol (Lausanne) 8(47):1\u20138. https:\/\/doi.org\/10.3389\/fendo.2017.00047","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"4391_CR39","doi-asserted-by":"publisher","first-page":"R139","DOI":"10.1530\/EC-21-0025","volume":"10","author":"JF Rehfeld","year":"2021","unstructured":"Rehfeld JF (2021) Cholecystokinin and the hormone concept. Endocr Connect 10(3):R139\u2013R150. https:\/\/doi.org\/10.1530\/EC-21-0025","journal-title":"Endocr Connect"},{"key":"4391_CR40","unstructured":"Reubi JC, Schaer JC , Waser B (1997) Cholecystokinin (CCK)-A and CCK-B\/gastrin receptors in human tumors. Cancer Res 57:1377\u20131386. http:\/\/cancerres.aacrjournals\/org\/content\/57\/7\/1377"},{"key":"4391_CR41","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/0196-9781(91)90184-Q","volume":"12","author":"P Sacerdote","year":"1991","unstructured":"Sacerdote P, Wiedermann CJ, Wahl LM, Pert CB, Ruff MR (1991) Visualization of cholecystokinin receptors on a subset of human monocytes and in rat spleen. Peptides 12:167\u2013176. https:\/\/doi.org\/10.1016\/0196-9781(91)90184-Q","journal-title":"Peptides"},{"key":"4391_CR42","doi-asserted-by":"publisher","first-page":"896029","DOI":"10.1155\/2014\/896029","volume":"2014","author":"RS Saia","year":"2014","unstructured":"Saia RS, Mestriner FL, Bertozi G, Cunha FQ, C\u00e1rnio EC (2014) Cholecystokinin inhibits inducible nitric oxide synthase expression by lipopolysaccharide-stimulated peritoneal macrophages. Mediat Inflamm 2014:896029. https:\/\/doi.org\/10.1155\/2014\/896029","journal-title":"Mediat Inflamm"},{"issue":"3","key":"4391_CR43","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/j.1476-5381.1989.tb11866.x","volume":"96","author":"C Scarpignato","year":"1989","unstructured":"Scarpignato C, Varga G, Dobronyi I, Papp M (1989) Effect of a new potent CCK antagonist, lorglumide, on caerulein- and bombesin-induced pancreatic secretion and growth in the rat. Br J Pharmacol 96(3):61\u2013669. https:\/\/doi.org\/10.1111\/j.1476-5381.1989.tb11866.x","journal-title":"Br J Pharmacol"},{"issue":"1\u20133","key":"4391_CR44","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/s0167-0115(01)00281-6","volume":"101","author":"F Schmitz","year":"2001","unstructured":"Schmitz F, Schrader H, Otte J, Schmitz H, St\u00fcber E, Herzig K, Schmidt WE (2001) Identification of CCK-B\/gastrin receptor splice variants in human peripheral blood mononuclear cells. Regul Pept 101(1\u20133):25\u201333. https:\/\/doi.org\/10.1016\/s0167-0115(01)00281-6","journal-title":"Regul Pept"},{"key":"4391_CR45","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.3390\/ijms24043625","volume":"24","author":"N Shivapurkar","year":"2023","unstructured":"Shivapurkar N, Gay MD, He A, Chen W, Golnazar S, Cao H, Duka T, Kallakury B, Vasudevan S, Smith JP (2023) Treatment with a cholecystokinin receptor antagonist, proglumide, improves efficacy of immune checkpoint antibodies in hepatocellular carcinoma. Int J Mol Sci 24:3625. https:\/\/doi.org\/10.3390\/ijms24043625","journal-title":"Int J Mol Sci"},{"key":"4391_CR46","doi-asserted-by":"publisher","first-page":"G91","DOI":"10.1152\/ajpgi.00301.2013","volume":"306","author":"JP Smith","year":"2014","unstructured":"Smith JP, Solomon TE (2014) Cholecystokinin and pancreatic cancer: the chicken or the egg? Am J Physiol Gastrointest Liver Physiol 306:G91\u2013G101. https:\/\/doi.org\/10.1152\/ajpgi.00301.2013","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"7","key":"4391_CR47","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1097\/MPA.0000000000000194","volume":"43","author":"JP Smith","year":"2014","unstructured":"Smith JP, Cooper TK, McGovern CO, Gilius EL, Zhong Q, Liao J, Molinolo AA, Gutkind JS, Matters GL (2014) Cholecystokinin receptor antagonist halts progression of pancreatic cancer precursor lesions and fibrosis in mice. Pancreas 43(7):1050\u20131059. https:\/\/doi.org\/10.1097\/MPA.0000000000000194","journal-title":"Pancreas"},{"key":"4391_CR48","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s00262-017-2077-9","volume":"67","author":"JP Smith","year":"2018","unstructured":"Smith JP, Wang S, Nadella S, Jablonski SA, Weiner LM (2018) Cholecystokinin receptor antagonist alters pancreatic cancer microenvironment and increases efficacy of immune checkpoint antibody therapy in mice. Cancer Immunol Immunother 67:195\u2013207. https:\/\/doi.org\/10.1007\/s00262-017-2077-9","journal-title":"Cancer Immunol Immunother"},{"key":"4391_CR49","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.3892\/or.14.4.1055","volume":"14","author":"M Stubbs","year":"2005","unstructured":"Stubbs M, Khan K, Wickremasinghe RG, Ganeshaguru K, Caplin ME (2005) CCK-2 gastrin receptor as a potential target for therapy in leukemia cell lines. Oncol Rep 14:1055\u20131058. https:\/\/doi.org\/10.3892\/or.14.4.1055","journal-title":"Oncol Rep"},{"issue":"4\u20136","key":"4391_CR50","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s00210-007-0200-8","volume":"377","author":"T Tanaka","year":"2008","unstructured":"Tanaka T, Katsuma S, Adachi T, Koshimizu TA, Hirasawa A, Tsujimoto G (2008) Free fatty acids induce cholecystokinin secretion through GPR120. Naunyn Schmiedebergs Arch Pharmacol 377(4\u20136):523\u2013527. https:\/\/doi.org\/10.1007\/s00210-007-0200-8","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"1","key":"4391_CR51","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10620-019-05722-3","volume":"65","author":"RD Tucker","year":"2020","unstructured":"Tucker RD, Ciofoaia V, Nadella S, Gay MD, Cao H, Huber M, Safronenka A, Shivapurkar N, Kallakury B, Kruger AJ, Kroemer AHK, Smith JP (2020) A cholecystokinin receptor antagonist halts nonalcoholic steatohepatitis and prevents hepatocellular carcinoma. Dig Dis Sci 65(1):189\u2013203. https:\/\/doi.org\/10.1007\/s10620-019-05722-3","journal-title":"Dig Dis Sci"},{"issue":"2","key":"4391_CR52","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s00280-017-3351-4","volume":"80","author":"M Ueno","year":"2017","unstructured":"Ueno M, Li CP, Ikeda M, Ishii H, Mizuno N, Yamaguchi T, Ioka T, Oh DY, Ichikawa W, Okusaka T, Matsuyama Y, Arai D, Chen LT, Park YS, Furuse J (2017) A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo. Cancer Chemother Pharmacol 80(2):307\u2013315. https:\/\/doi.org\/10.1007\/s00280-017-3351-4","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1\u20132","key":"4391_CR53","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ejphar.2007.02.003","volume":"562","author":"A Varga","year":"2007","unstructured":"Varga A, Bagossi P, T\u0151zs\u00e9r J, Peitl B, Szilv\u00e1ssy Z (2007) Effect of experimental hypercholesterolaemia on K+ channel alpha-subunit mRNA levels in rabbit hearts. Eur J Pharmacol 562(1\u20132):130\u2013131. https:\/\/doi.org\/10.1016\/j.ejphar.2007.02.003","journal-title":"Eur J Pharmacol"},{"key":"4391_CR54","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.3390\/ijms25042338","volume":"25","author":"T Vilari\u00f1o-Garc\u00eda","year":"2024","unstructured":"Vilari\u00f1o-Garc\u00eda T, Polonio-Gonz\u00e1lez ML, P\u00e9rez-P\u00e9rez A, Ribalta J, Arrieta F, Aguilar M, Obaya JC, Gimeno-Orna JA, Iglesias P, Navarro J (2024) Role of leptin in obesity, cardiovascular disease, and type 2 diabetes. Int J Mol Sci 25:2338. https:\/\/doi.org\/10.3390\/ijms25042338","journal-title":"Int J Mol Sci"},{"issue":"4","key":"4391_CR55","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/bjc.1993.123","volume":"67","author":"P Watanapa","year":"1993","unstructured":"Watanapa P, Flaks B, Oztas H, Deprez PH, Calam J, Williamson RC (1993) Inhibitory effect of a cholecystokinin antagonist on pancreatic carcinogenesis after pancreatobiliary diversion. Br J Cancer 67(4):663\u2013667. https:\/\/doi.org\/10.1038\/bjc.1993.123","journal-title":"Br J Cancer"},{"issue":"2","key":"4391_CR56","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1097\/MPA.0000000000000974","volume":"47","author":"M Xu","year":"2018","unstructured":"Xu M, Jung X, Hines OJ, Eibl G, Chen Y (2018) Obesity and pancreatic cancer: overview of epidemiology and potential prevention by weight loss. Pancreas 47(2):158\u2013162. https:\/\/doi.org\/10.1097\/MPA.0000000000000974","journal-title":"Pancreas"},{"key":"4391_CR57","doi-asserted-by":"publisher","unstructured":"Xu SJ, Gao WJ, Cong B, Ma CL, Li SJ, Ling YL, Gu ZY, Yao YX (2005) Effect of cholecystokinin octapeptide on diacylglycerol-PKC signaling pathway in rat pulmonary interstitial macrophages stimulated by lipopoly saccharide. Acta Pharmacol Sin 26(12):1497\u20131504. https:\/\/doi.org\/10.1111\/j.1745-7254.2005.00217.x","DOI":"10.1111\/j.1745-7254.2005.00217.x"},{"key":"4391_CR58","doi-asserted-by":"publisher","first-page":"112","DOI":"10.3389\/fendo.2020.00112","volume":"11","author":"Q Zeng","year":"2020","unstructured":"Zeng Q, Ou L, Wang W, Guo D-Y (2020) Gastrin, cholecystokinin, signaling, and biological activities in cellular processes. Front Endocrinol 11:112. https:\/\/doi.org\/10.3389\/fendo.2020.00112","journal-title":"Front Endocrinol"},{"issue":"3","key":"4391_CR59","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s00430-014-0328-3","volume":"203","author":"FMGC Zuelli","year":"2014","unstructured":"Zuelli FMGC, C\u00e1rnio EC, Saia RS (2014) Cholecystokinin protects rats against sepsis induced by Staphylococcus aureus. Med Microbiol Immunol 203(3):165\u2013176. https:\/\/doi.org\/10.1007\/s00430-014-0328-3","journal-title":"Med Microbiol Immunol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04391-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04391-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04391-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T22:05:49Z","timestamp":1771538749000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04391-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["4391"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04391-6","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,30]]},"assertion":[{"value":"4 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The experiments performed in the present work conform to the guiding principles of the European Community for the care and use of laboratory animals regulated under Directive 2010\/63\/EU and conform to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85\u201323, revised 1996). All experimental protocols applied and have been approved by the Ethics Committee of the University of Debrecen, Hungary (approval number: 13\/2022\/DEM\u00c1B).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}